INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
INSMED Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$95.29−0.98 (-1.02%)
Close on Oct 19, 2026
- Market cap
- $20.71B
- P/E (TTM)
- –
- Dividend yield
- –
INSMED Inc revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BRINSUPRI | $309.17M | $207.85M | $144.61M | $28.05M | $0 | $0 | $0 | $0 | – | – | – | – | 72.7% | – |
| ARIKAYCE external R&D expenses | $116.32M | $98.11M | $119.24M | $114.29M | $107.42M | $92.82M | $104.44M | $93.43M | – | – | – | – | 27.3% | +8.3% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $378.74M | $270.07M | $217.96M | $102.04M | $68.68M | $64.28M | $67.79M | $66.87M | $63.79M | $56.35M | $58.26M | $59.20M | 89.0% | +451.4% |
| International | $46.75M | $35.90M | $45.88M | $40.31M | $38.73M | $28.55M | $36.65M | $26.56M | – | – | – | – | 11.0% | +20.7% |
| Japan | – | – | – | – | $30.67M | $22.08M | $30.71M | $20.98M | $21.11M | $14.89M | $20.95M | $16.03M | – | – |
| Europe and rest of world | – | – | – | – | $8.06M | $6.47M | $5.94M | $5.57M | $5.44M | $4.26M | $4.48M | $3.84M | – | – |
From the segment and revenue-disaggregation notes of Insmed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.